Pharmaceutical News

SUMMIT, N.J.--(BUSINESS WIRE)--Jan. 23, 2012-- The contact information of release should read: Celgene Corporation Investors: 908-673-9628 investors@celgene.com or Media: 908-673-2275 media@celgene.com. The corrected release reads: CELGENE CORPORATION ELECTS DR. RICHARD W. BARKER TO ITS BOARD OF DIRECTORS Celgene Corporation (NASDAQ: CELG) today announced the election of Richard W. Barker, D.Phil., to its Board of Directors. Dr. Barker is a global thought leader in healthcare systems and government policy. He served as Director General of the Association of the British Pharmaceutical Indu...

SUMMIT, N.J.--(BUSINESS WIRE)--Jan. 23, 2012-- Celgene Corporation (NASDAQ: CELG) today announced the election of Richard W. Barker, D.Phil., to its Board of Directors. Dr. Barker is a global thought leader in healthcare systems and government policy. He served as Director General of the Association of the British Pharmaceutical Industry (ABPI), and as a board member for the European and International pharmaceutical industry federations, addressing critical issues and working closely with government health agencies. During his career, Dr. Barker was Chief Executive of Chiron Diagnostics, General Manager of IBM’s Worldwide Healthcare Solutions division and leader of McKinsey & Company’s...

2012 Total Revenue Guidance $5.4-$5.6B, up ~15%, REVLIMID® $3.75B to $3.85B, up ~19%, and Non-GAAP EPS $4.70 - $4.80, up ~25% Outlook for 2012 Includes Significant Catalysts in Hematology, Oncology, and Inflammation and Immunology 2011 Record Results with Total Revenue of Over $4.8B, up 34%, and Non-GAAP EPS of approximately $3.79, up 36% 2015 Outlook Updated to $8-9B Total Revenue and Non-GAAP EPS of $8.00 to $9.00 SUMMIT, N.J.--(BUSINESS WIRE)--Jan. 9, 2012-- Celgene Corporation (NASDAQ: CELG) today reviewed 2011 achievements and provided its outlook for 2012 at the JPMorgan 30th Annua...

SUMMIT, N.J.--(BUSINESS WIRE)--Dec. 28, 2011-- Celgene Corporation (NASDAQ: CELG) today announced its presentations at two upcoming investor conferences will be webcast live and will be available in the investor relations section of the company’s Web site at www.celgene.com. Celgene management will provide an overview of the company. On Thursday, January 5, 2012, Celgene will present at the Goldman Sachs Healthcare CEOs Unscripted Conference at 3:15 p.m. ET. On Monday, January 9, 2012, Celgene will present at the 30th Annual J.P. Morgan Healthcare Conference at 11:00 a.m. ET. Celgene Corporation...

SUMMIT, N.J.--(BUSINESS WIRE)--Dec. 22, 2011-- Celgene Corporation (NASDAQ: CELG) today announced the appointment of Richard Bagger as Senior Vice President, Corporate Affairs and Strategic Market Access, effective January 30th. Mr. Bagger will be responsible for all government and public affairs, strategic market access, communications and patient advocacy initiatives and will report to Robert J. Hugin, Chairman and Chief Executive Officer of Celgene Corporation. The position of Senior Vice President, Corporate Affairs and Strategic Market Access is a newly created position at Celgene established to support the Company’s glo...

Celgene and GELA Announce Initiation of RELEVANCE(R) Phase III Study in Follicular Lymphoma BOUDRY, Switzerland, Dec 14, 2011 (BUSINESS WIRE) --Celgene International Sàrl (Nasdaq: CELG) and the Groupe d'Etude des Lymphomes de l'Adulte (GELA) today announced the organizations have initiated an international, Phase III, open-label, randomized study to evaluate the therapeutic potential of a novel chemotherapy-free approach for the treatment of follicular lymphoma (FL). The combination of REVLIMID (lenalidomide) and rituximab, also referred to as the R-squared (or R2) regimen pioneered by Nathan Fowler, MD and colleagues ...

Celgene and GELA Announce Initiation of RELEVANCE® Phase III Study in Follicular Lymphoma BOUDRY, Switzerland--(BUSINESS WIRE)--Dec. 14, 2011-- Celgene International Sàrl (Nasdaq: CELG) and the Groupe d’Etude des Lymphomes de l’Adulte (GELA) today announced the organizations have initiated an international, Phase III, open-label, randomized study to evaluate the therapeutic potential of a novel chemotherapy-free approach for the treatment of follicular lymphoma (FL). The combination of REVLIMID (lenalidomide) and rituximab, also referred to as the R-squared (or R2) regimen pioneered by Nathan Fowler, MD and colleagues...

The Study Reported Overall Response Rate of 66%, With 12% of Patients Achieving Complete Response After a Median follow-up of 31 Months, Overall Survival Was 75% BOUDRY, Switzerland--(BUSINESS WIRE)--Dec. 13, 2011-- Celgene International Sàrl, a subsidiary of Celgene Corporation, (NASDAQ: CELG), announced final results from a phase II investigational study evaluating the combination of REVLIMID® (lenalidomide) and rituximab in 59 patients with relapsed or refractory chronic lymphocytic leukemia (CLL). These data were presented at the 53rd Annual Meeting of the American Society of Hematology in San Dieg...

Three Year Overall Survival from Inclusion Was 93% for Patients Treated with REVLIMID(R) and Dexamethasone Compared to 76% for Patients under Observation Only BOUDRY, Switzerland, Dec 13, 2011 (BUSINESS WIRE) --Celgene International Sàrl, a subsidiary of Celgene Corporation (NASDAQ: CELG), announced that updated data evaluating continuous treatment with REVLIMID(R) (lenalidomide) in patients with high-risk asymptomatic smoldering multiple myeloma were presented at the 53rd Annual Meeting of the American Society of Hematology. The study demonstrated that early treatment with lenalidomide and dexamethasone followed by co...

Three Year Overall Survival from Inclusion Was 93% for Patients Treated with REVLIMID® and Dexamethasone Compared to 76% for Patients under Observation Only BOUDRY, Switzerland--(BUSINESS WIRE)--Dec. 13, 2011-- Celgene International Sàrl, a subsidiary of Celgene Corporation (NASDAQ: CELG), announced that updated data evaluating continuous treatment with REVLIMID® (lenalidomide) in patients with high-risk asymptomatic smoldering multiple myeloma were presented at the 53rd Annual Meeting of the American Society of Hematology. The study demonstrated that early treatment with lenalidomide and dexamethasone followed...